Articles By Md Yuzaiful Md Yusof, MRCP(UK), PhD
De BiTE a TriTE: Avances de los activadores de linfocitos T en las ERM
El Congreso EULAR 2026 en Londres mostró un creciente interés en los activadores de linfocitos T como una estrategia novedosa para lograr una depleción profunda de linfocitos B y una remisión libre de fármacos en las enfermedades reumáticas y musculoesqueléticas (ERM) refractarias. Los activadores biespecíficos de linfocitos T (BiTE) tienen como objetivo superar las limitaciones de las terapias con linfocitos T con CAR mediante la disponibilidad inmediata, la toxicidad reversible debido a la corta semivida de estos anticuerpos monoclonales, la evitación de la necesidad de acondicionamiento/linfodepleción y un menor coste.
Read Article
From BiTE to TriTE: Progress of T-cell Engagers in RMDs
The EULAR 2026 Congress in London showcased growing interest in T-cell engagers as a novel strategy to achieve deep B-cell depletion and drug-free remission in refractory rheumatic and musculoskeletal diseases (RMDs).
Read Article
5 años desde el Paciente ID001: Avances en la terapia CAR-T en ERM
Cinco años después, ¿estamos más cerca de la autorización de la primera terapia CAR-T en enfermedades reumáticas y musculoesqueléticas (ERM)?
Read Article
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read Article
Progress of biologics/targeted therapy in SLE
We are in a transformative era in SLE which generates excitement to both physicians and people living with lupus. We now have four licensed biologics/targeted therapies (i.e., belimumab, voclosporin and obinutuzumab for active lupus nephritis, and belimumab and anifrolumab for active non-renal SLE). Moreover, many other agents with different mode of action and administration are in late phase trials. This article previews some data being presented at EULAR 2026 Congress in London.
Read Article
Avances de los tratamientos biológicos/dirigidos en el LES
Estamos en una era de transformación en el LES que genera entusiasmo tanto en los médicos como en las personas que viven con lupus. Ahora disponemos de cuatro terapias biológicas/dirigidas autorizadas (es decir, belimumab, voclosporina y obinutuzumab para la nefritis lúpica activa, y belimumab y anifrolumab para el LES no renal activo). Además, muchos otros fármacos con diferentes modos de acción y administración se encuentran en fases avanzadas de ensayo. Este artículo presenta un avance de algunos datos que se expondrán en el Congreso EULAR 2026 en Londres.
Read Article
Beyond malignancy, look out for LICATS with CAR-T
CAR T cell therapy took the centre stage in 2022 where data pertaining to a successful case series of 5 patients with refractory SLE were published by Prof Schett’s group. Since then, this area of therapeutic has expanded exponentially. Our growing enthusiasm was slightly dampened though when the FDA required all six approved CAR T-cell therapies in oncology to include a black box warning regarding the risk of second primary malignancies in January 2024. At ACR25, Prof Schett’s group described a new form of toxicity in patients with autoimmune disease receiving CAR T-cell therapy, most likely due to the cleansing of immune cells from the affected organs.
Read Article
Sjogren’s disease: two drugs with positive trials
After several failures of therapies in Phase 3 trials of Sjogren’s disease (SjD) over many years, all hope is not lost!
Read Article
SLE Conference Preview: progress in biologics
The pharmacology treatment including biologics, cellular-based therapies, and Bi-specific T-cell Engager (BiTE) in systemic lupus erythematosus (SLE) is a rapidly expanding field of research that provides excitement and optimism to both the patients and the physicians.
Read Article
ICYMI: SLE: advances to achieve deep B-cell depletion
The race is on for the first chimeric antigen receptor (CAR)-based therapy to be approved for the treatment of systemic lupus erythematosus. Its main principle is to induce deep B-cell depletion, with the hope to reset the B-cell aberrant immunity for a sustained clinical remission. At EULAR 2025 in Barcelona, several advances of CAR-based therapies will be presented.
Read Article
